EBElisabetta Bianchini

Elisabetta Bianchini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elisabetta Bianchini has a total of 259 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Overcoming the opaque side of AI in healthcare: a lifecycle-based approach

    by Elisabetta Bianchini, Lucia Billeci, Noemi Conditi, Florinda Coro, Alice Ravizza

    1. Artificial intelligence/machine learning (AI/ML)-enabled medical devices are increasingly used in the healthcare domain. These technologies can potentially facilitate earlier disease detection a...

  • Open Access

    Tonometer- and ultrasound-based pulse wave analysis – a comparative study

    by Stefan Orter, Elisabetta Bianchini, Siegfried Wassertheurer, Smriti Badhwar, Bernhard Hametner, Sara Sinceri, Martin Bachler, Lorenzo Ghiadoni, Pierre Boutouyrie, Giacomo Aringhieri, et al.

  • Open Access

    Integrating Structural and Functional Ultrasound Carotid Assessment in a Single Software Platform: Development and Feasibility Evaluation

    by Elisabetta Bianchini, Stefan Orter, Siegfried Wassertheurer, Bernhard Hametner, Martin Bachler, Mauro Andretta, Smriti Badhwar, Rosa Maria Bruno, Lorenzo Ghiadoni, Gennaro D’ANgelo, et al.

  • Open Access

    A regulation-based project lifecycle for innovative medical devices: Delphi consensus from an Italian expert panel

    by Maria Raffaella Martina, Mattia Barsanti, Marco Praticò, Salvatore Tallarico, Francesca Giambi, Francesca Rossi, Luisa Pellegrini, Elisabetta Bianchini, Silvia Asaro, Benedetta Becherini, et al.


  • Open Access

    Developing technologies to assess vascular ageing: a roadmap from VascAgeNet

    by Serena Zanelli, Davide Agnoletti, Jordi Alastruey, John Allen, Elisabetta Bianchini, Vasiliki Bikia, Pierre Boutouyrie, Rosa Maria Bruno, Rachel Climie, Djammaleddine Djeldjli, et al.

    Vascular ageing (vascular ageing) is the deterioration of arterial structure and function which occurs naturally with age, and which can be accelerated with disease. Measurements of vascular ageing are emerging as markers of cardiovascular risk, with potential applications in disease diagnosis and prognosis, and for guiding treatments. However, vascular ageing is not yet routinely assessed in clinical practice. A key step towards this is the development of technologies to assess vascular ageing. In this Roadmap, experts discuss several aspects of this process, including: measurement technologies; the development pipeline; clinical applications; and future research directions. The Roadmap summarises the state of the art, outlines the major challenges to overcome, and identifies potential future research directions to address these challenges.


  • Top Cited Papers
    Open Access

    2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices

    by Bart Spronck, Dimitrios Terentes-Printzios, Alberto P. Avolio, Pierre Boutouyrie, Andrea Guala, Ana Jerončić, Stéphane Laurent, Eduardo C.D. Barbosa, Johannes Baulmann, Chen-Huan Chen, et al.

    BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations. METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices. RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice. CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.


  • Magnetic Resonance Imaging and Computed Tomography for the Noninvasive Assessment of Arterial Aging: A Review by the VascAgeNet COST Action

    by Elisabetta Bianchini, Mai Tone Lønnebakken, Peter Wohlfahrt, Senol Piskin, Dimitrios Terentes‐Printzios, Jordi Alastruey, Andrea Guala

    Magnetic resonance imaging and computed tomography allow the characterization of arterial state and function with high confidence and thus play a key role in the understanding of arterial aging and its translation into the clinic. Decades of research into the development of innovative imaging sequences and image analysis techniques have led to the identification of a large number of potential biomarkers, some bringing improvement in basic science, others in clinical practice. Nonetheless, the complexity of some of these biomarkers and the image analysis techniques required for their computation hamper their widespread use. In this narrative review, current biomarkers related to aging of the aorta, their founding principles, the sequence, and postprocessing required, and their predictive values for cardiovascular events are summarized. For each biomarker a summary of reference values and reproducibility studies and limitations is provided. The present review, developed in the COST Action VascAgeNet, aims to guide clinicians and technical researchers in the critical understanding of the possibilities offered by these advanced imaging modalities for studying the state and function of the aorta, and their possible clinically relevant relationships with aging.


  • Open Access

    The Ultrasound Window Into Vascular Ageing: A Technology Review by the VascAgeNet COST Action

    by Elisabetta Bianchini, Andrea Guala, Spyretta Golemati, Jordi Alastruey, Rachel E. Climie, Kalliopi Dalakleidi, Martina Francesconi, Dieter Fuchs, Yvonne Hartman, Afrah E.F. Malik, et al.

    Non‐invasive ultrasound (US) imaging enables the assessment of the properties of superficial blood vessels. Various modes can be used for vascular characteristics analysis, ranging from radiofrequency (RF) data, Doppler‐ and standard B/M‐mode imaging, to more recent ultra‐high frequency and ultrafast techniques. The aim of the present work was to provide an overview of the current state‐of‐the‐art non‐invasive US technologies and corresponding vascular ageing characteristics from a technological perspective. Following an introduction about the basic concepts of the US technique, the characteristics considered in this review are clustered into: 1) vessel wall structure; 2) dynamic elastic properties, and 3) reactive vessel properties. The overview shows that ultrasound is a versatile, non‐invasive, and safe imaging technique that can be adopted for obtaining information about function, structure, and reactivity in superficial arteries. The most suitable setting for a specific application must be selected according to spatial and temporal resolution requirements. The usefulness of standardization in the validation process and performance metric adoption emerges. Computer‐based techniques should always be preferred to manual measures, as long as the algorithms and learning procedures are transparent and well described, and the performance leads to better results. Identification of a minimal clinically important difference is a crucial point for drawing conclusions regarding robustness of the techniques and for the translation into practice of any biomarker.


  • Open Access

    Medical Device Regulation: Should We Care About It?

    by Elisabetta Bianchini, Christopher Clemens Mayer

    Medical devices are subject to strict regulatory and approval processes to enter the market and to be used by operators and patients. These are needed to guarantee the users’ safety. The different activities of these processes have important implications for all involved stakeholders and for the whole lifecycle of a medical device. The aim of this work is to provide an overview of some key aspects of the new EU Medical Device Regulation and to show why researchers, innovators and clinicians should care about it. Awareness of regulatory requirements can improve the innovation process and its efficiency in terms of both social and ethical impact, but this awareness needs to be raised in the upcoming months and years. One can shortly say “yes, one needs to take care” of the new EU Medical Device Regulation. First and foremost, it is crucial for the sake of the users’ safety, which is the regulation’s intrinsic goal. Second, it should not just be seen as an obstacle for new innovations in the medical domain, but as a chance as it can provide new opportunities.